{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.8"},{"groupId":"OG001","value":"45.0"}]}],"title":"Confirmed Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Confirmed Complete Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"NUMBER","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Best Overall Response (BoR) , Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Percentage"}